Clinical trial
Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush…
NCT00002394 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00002394 |
|---|---|
| Title | Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment |
| Official title | A Four-Week, Open-Label, Non-Randomized, Multicenter, Dose-Finding, Pilot Study to Evaluate the Safety and Efficacy of Two Daily Doses of Lamisil (1500 Mg and 2000 Mg), Administered for a Maximum of 4 Weeks in HIV-Positive Subjects With Oral Mucosal Candidiasis Not Having Responded to a Minimum of… |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Candidiasis, Oral, HIV Infections |
| Intervention type | Drug |
| Interventions | Terbinafine hydrochloride |
| Enrollment | 30 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: